Project Grant HT94252411038
Award Date
11/1/24
Completion Date
10/31/26
Dollars Obligated
$320K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This federal Project Grant award of $249,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is supporting research conducted by the University of Maryland, Baltimore (UMB) to gain insights into multiple sclerosis pathology. The research project will leverage 7-T MRI and multiomics analysis of serologic samples to advance the understanding of this neurological disorder. The award period runs from August 15, 2024 to August 14,...
This federal Project Grant award, valued at $1,599,997.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The award was granted to the University of Illinois to conduct clinical trials related to multiple sclerosis research. The project aims to explore innovative approaches to...
This Project Grant award of $999,996.00 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) is supporting research at the University of Illinois to investigate the mechanism governing the association between viral respiratory infection relapse and disease progression in persons with multiple sclerosis (MS). The research aims to transform health care for service members and the American public through innovative and impactful research, as...
The U.S. Department of Defense's Defense Health Agency awarded a $250,000 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "EPSTEIN-BARR VIRUS IN PATIENTS WITH NEW-ONSET MULTIPLE SCLEROSIS". The project will run from July 1, 2024 to June 30, 2026. As a prime grantee, Yale University will lead this scientific research effort to advance knowledge about the relationship between Epstein-Barr virus and the...
This federal Project Grant award, with an ID of HT94252410926, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The $293,978 award will support a 2-year research project at the University of Illinois to investigate the relationship between cognition, vascular function, and physical activity in individuals with multiple sclerosis. The research aims to transform healthcare for military service members and the general...
This federal Project Grant award of $997,060 from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research at the University of California, San Francisco (UCSF) to develop a new understanding of selective neuron vulnerability and neuroprotection in progressive multiple sclerosis. The award has a performance period from September 15, 2024 to September 14, 2027. As a leading academic medical center and research institution, UCSF will leverage...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $993,283.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on "Proteomic Determinants and Components of Progression in Multiple Sclerosis". The 2-year award, effective from Sep 1, 2025 to Aug 31, 2027, will support advanced biomedical research initiatives focused on transforming healthcare for...
This Project Grant award of $999,983.00 from the Defense Health Agency supports research by The Leland Stanford Junior University (Stanford University) to analyze Epstein-Barr virus (EBV) genomes, epigenomes, and EBV-dependent B cell proteomes. The goal is to identify fundamental viral triggers of multiple sclerosis (MS). The 3-year project will run from July 1, 2023 to June 30, 2026. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports...
The federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Brigham & Women's Hospital Inc. provides $319,542.00 in funding to research the modulation of epigenetic regulators controlling pathogenic astrocytes for the treatment of multiple sclerosis (MS). The research, which will be conducted from November 1, 2024 to October 31, 2026, aims to develop innovative approaches to disease prevention, diagnosis, and treatment for...
The Department of the Army Medical Command awarded a $319,938 project grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University. The grant, with a performance period from September 1, 2024 to August 31, 2026, will fund a large-scale MRI-based study to determine multiple sclerosis-specific atrophy phenotypes. This research aims to transform healthcare for military service members and the broader public by advancing the understanding and...